Ascendis Pharma A (ASND) Enterprise Value (2016 - 2025)
Ascendis Pharma A (ASND) has disclosed Enterprise Value for 10 consecutive years, with -$717.1 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 19.93% to -$717.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$717.1 million through Dec 2025, down 19.93% year-over-year, with the annual reading at -$717.1 million for FY2025, 19.93% down from the prior year.
- Enterprise Value hit -$717.1 million in Q4 2025 for Ascendis Pharma A, down from -$597.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$429.8 million in Q4 2023 to a low of -$780.3 million in Q4 2021.
- Historically, Enterprise Value has averaged -$655.1 million across 5 years, with a median of -$717.1 million in 2025.
- Biggest five-year swings in Enterprise Value: soared 42.72% in 2023 and later plummeted 39.13% in 2024.
- Year by year, Enterprise Value stood at -$780.3 million in 2021, then rose by 3.83% to -$750.3 million in 2022, then skyrocketed by 42.72% to -$429.8 million in 2023, then tumbled by 39.13% to -$597.9 million in 2024, then decreased by 19.93% to -$717.1 million in 2025.
- Business Quant data shows Enterprise Value for ASND at -$717.1 million in Q4 2025, -$597.9 million in Q4 2024, and -$429.8 million in Q4 2023.